HRT and Endometriosis: When “No Uterus, No Progestogen” Doesn’t Apply to You

The HRT Index Editorial TeamIndependent women's health research

Last reviewed: August 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 6, 2026 · Last verified: August 6, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Match the HRT decision to your surgical history

Find My HRT Path helps organize the care route by anatomy, symptoms, risk history, budget, and state. It cannot review an operative report, evaluate new pelvic symptoms, or replace specialist care.

Find My HRT Path

HRT and endometriosis are not automatically incompatible. FDA-approved estrogen labels we checked say some hysterectomized women with an endometriosis history may benefit from a progestogen. ESHRE and EMAS prefer combined therapy; BMS allows a narrow estrogen-only path after initial combined therapy when little or no disease remains. Your operative report, age, anatomy, symptoms, and other risks decide the conversation.

Best for: women deciding about menopausal HRT after endometriosis, hysterectomy, ovary removal, or surgical menopause.

Not for you if: you have new pelvic pain, a pelvic mass, blood in your urine or stool, severe or rapidly worsening pain, unexplained weight loss, or any bleeding after menopause. Those symptoms need prompt in-person evaluation before an online HRT decision.

This page contains links to provider reviews that may contain labeled affiliate links. If you later start care through one, The HRT Index may earn a commission at no extra cost to you. How we make money →

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

HRT and endometriosis: which situation are you in?

Your situation	What current U.S. estrogen labeling says	What current European guidance says	What actually decides the next conversation
Uterus and ovaries removed, known residual disease	Representative labels say to consider adding a progestogen	ESHRE and EMAS say avoid estrogen-only; BMS prefers continuous combined HRT	Where the disease remains, your age, symptoms, and competing risks
Uterus and ovaries removed, little or no residual disease documented	A history of endometriosis can still trigger the label exception	ESHRE and EMAS still prefer combined therapy; BMS allows a narrow later estrogen-only option after initial continuous-combined HRT, especially beyond the natural menopause age	What “complete” means in the operative report, how long ago surgery occurred, and your breast-risk profile
Uterus still present, endometriosis history	Systemic estrogen needs endometrial protection with a progestogen	Continuous combined therapy is generally preferred	Which progestogen and schedule you tolerate, plus how active the endometriosis is
Both ovaries removed, uterus retained	A progestogen is needed for the uterine lining	Same combined-therapy preference	Two separate reasons now apply: uterine protection and the endometriosis history
No prior endometriosis diagnosis, new pelvic symptoms after menopause	A drug-label choice does not diagnose the cause	EMAS calls surgery the preferred option for symptomatic postmenopausal endometriosis; ESHRE says surgery may be considered to establish diagnosis and address malignancy risk	Evaluation first, not choosing an HRT regimen

That’s the answer. Here’s what changes it.

Five things that move this decision:

How much endometriosis was left behind at your last surgery. This is the big one, and it is usually documented somewhere you can get.
Whether you still have a uterus. That changes why a progestogen is needed, but it does not settle what residual endometriosis means.
Your age when your ovaries came out. Losing ovarian function before the usual menopause age changes the cost of leaving symptoms and estrogen loss untreated.
Your breast cancer, clotting, liver, and cardiovascular history. Adding a progestogen is not a free move, and estrogen is not appropriate for everyone.
Where you live. Tibolone appears throughout European guidance but has no FDA-approved product in the United States.

Here’s the part almost nobody tells you: one document can change this conversation more than any generic rule — your operative report. It cannot prove that no microscopic disease exists, but it can show whether visible disease was completely excised, deliberately left behind, or never addressed.

How do you know whether online HRT care is the right starting point?

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

The tool takes about 90 seconds, does not require an email, and does not store your health answers. It routes; it does not diagnose or prescribe.

What did we actually verify for this page?

We did not summarize other people’s summaries. Here is the work behind this page, completed on August 6, 2026:

Read the current Divigel prescribing information line by line. The DailyMed record is version 31, effective February 27, 2026. We checked Sections 2.1, 4, 5.13, the recent-major-changes block, and patient labeling.
Checked the endometriosis language across representative current estrogen labels. We confirmed it on Divigel, Enjuvia, Premarin tablets, and a current generic estradiol patch label. We did not turn that sample into the false claim that every estrogen product has identical wording or section numbers.
Confirmed the exception on a current patch label. A current estradiol transdermal-system label contains the hysterectomy/endometriosis exception and a named “Exacerbation of Endometriosis” warning.
Checked Bijuva separately instead of assuming a class-wide match. The current February 2026 Bijuva label is indicated for a woman with a uterus and does not carry the same standalone clinician-facing endometriosis section found on the estrogen-alone labels above.
Read the full 2025 EMAS clinical guide. It is publicly available, not paywalled. We also checked the 2022 ESHRE guideline and the British Menopause Society’s February 2026 clinician tool.
Rebuilt the outcome evidence ledger. Five published reports compare regimens or outcomes after surgery, but the 2003 and 2022 Thai reports include overlapping patients. We disclose that instead of adding them as independent evidence.
Re-verified the provider facts used near the end. Midi’s cash visit prices, PPO language, Medicare and Medicaid limits, Sesame’s cash-pay terms, and Sesame’s cancellation windows were checked against current provider pages. Anything those pages do not promise — including operative-report review — is labeled as something to confirm before paying.

What we still cannot turn into a number: your personal recurrence risk, your personal malignant-transformation risk, the ideal time to start HRT after surgery, the best progestogen molecule for residual endometriosis, or the exact duration a hysterectomized woman should stay on a progestogen. Current guidance says those questions remain uncertain.

Can you take HRT if you have a history of endometriosis?

A history of endometriosis is not listed as a contraindication in the representative current U.S. estrogen labels we checked. It appears in warnings and prescribing considerations instead. That changes which regimen gets discussed; it does not automatically make menopausal hormone therapy unavailable.

That distinction matters more than it sounds.

A contraindication is a hard stop written in Section 4 of a drug label. The current Divigel prescribing information lists:

Undiagnosed abnormal genital bleeding
Breast cancer or a history of breast cancer
Estrogen-dependent neoplasia
Active deep-vein thrombosis or pulmonary embolism, or a history of either
Active arterial thromboembolic disease such as stroke or heart attack, or a history of either
Anaphylactic reaction, angioedema, or hypersensitivity to the product
Hepatic impairment or disease
Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders

Endometriosis is not on that list.

A warning is different. It means the issue is real enough to change the prescribing conversation. Endometriosis has its own warning section on current Divigel and on the representative estradiol patch label we checked.

So why do women still get told flat no?

Sometimes the ordinary uterus-based shortcut gets applied before anyone asks where the endometriosis was or what surgery actually removed. Sometimes a clinician is following ESHRE or EMAS, which take a firm position against estrogen-only therapy. Sometimes the evidence is thin enough that two careful clinicians can read the same record and make different risk judgments.

You are not being difficult. The shortcut genuinely does not fit you.

What does the FDA label say about HRT and endometriosis?

Current FDA-approved estrogen labeling creates a specific exception to the usual “no uterus, no progestogen” rule. Divigel’s dosing section says some hysterectomized women with an endometriosis history may benefit from a progestogen, while its warning tells prescribers to consider one when residual disease is known.

This is the part we could not find explained clearly on a single consumer page, so we are going to show you exactly where it is.

It is in the dosing section — not buried

Section 2.1 of the current Divigel label is called “Important Use Information.” It says a woman without a uterus generally does not need a progestogen with estrogen. In the next sentence, it says that some hysterectomized women with a history of endometriosis “may benefit” from adding one and points to Section 5.13.

The exception is not a footnote. It is in the instructions.

The warning has its own heading

Section 5.13 is titled “Exacerbation of Endometriosis.” It reports a small number of malignant transformations of residual implants in women treated after hysterectomy with estrogen alone and tells the prescriber to consider progestogen therapy when residual endometriosis is known.

Read that distinction carefully:

Section 2.1 uses history of endometriosis.
Section 5.13 focuses on known residual endometriosis.

The label does not tell your prescriber which progestogen to use, what dose to choose, how long to use it, or how much risk the addition removes. It raises the exception; it does not finish the decision.

The February 2026 detail that proves the language survived an active rewrite

On February 12, 2026, the FDA announced approved label changes for six menopause hormone products. Risk statements about cardiovascular disease, breast cancer, and probable dementia were removed from the boxed warning on those products; the endometrial-cancer warning for systemic estrogen-only products remained.

The current Divigel label records February 2026 revisions to dosing, contraindications, and several warning sections. The prior general warning called “Addition of a Progestogen When a Woman Has Not Had a Hysterectomy” was removed. The endometriosis warning remained and shifted from Section 5.14 to 5.13 because the section above it disappeared.

The endometriosis exception survived the rewrite.

One wording change also matters. An older Divigel label said a hysterectomized woman with endometriosis “may need” a progestin. The 2026 label says she “may benefit” from a progestogen. That is softer language. We are telling you because it is checkable and because pretending the wording did not change would overstate the label.

It is not just one gel

Current product label checked	Route	What we verified
Divigel	Estradiol gel	Section 2.1 contains the hysterectomy/endometriosis exception; Section 5.13 addresses residual disease
Enjuvia	Oral synthetic conjugated estrogens	Current 2026 dosing language contains the same “may benefit” exception and points to its endometriosis warning
Premarin tablets	Oral conjugated estrogens	Section 5.16 says to consider adding a progestin for known residual endometriosis after hysterectomy
Estradiol transdermal system	Patch	Dosing language contains the exception; Section 5.14 is titled “Exacerbation of Endometriosis”
Bijuva	Fixed oral estradiol plus progesterone	Indicated for a woman with a uterus; the current clinician label does not contain the same standalone endometriosis section. It is not evidence that every estrogen-containing label is identical

The useful conclusion is not “all labels are the same.” It is this: the exception is present on multiple current systemic estrogen labels, including a patch. Check the exact product your pharmacy dispensed.

Go to DailyMed and search the brand or generic name, dosage form, strength, and manufacturer. If you need to confirm FDA approval, use Drugs@FDA or the Orange Book. An NDC number alone does not prove that a finished drug product is FDA-approved.

Why doesn’t “no uterus, no progestogen” automatically apply after endometriosis?

The standard rule is about protecting the uterine lining. Endometriosis involves endometrium-like tissue outside the uterus, so removing the uterus does not prove that every estrogen-responsive implant was removed. In this setting, a progestogen may be discussed for a different reason: residual disease rather than endometrial protection.

Think about what a progestogen usually does in menopausal HRT. Systemic estrogen stimulates the uterine lining. Long-term unopposed estrogen raises endometrial-cancer risk in a woman with a uterus. A progestogen reduces that risk. No uterus, no uterine lining, no endometrial-protection job.

Now your situation. Your endometriosis may have been on the ovaries, pelvic sidewall, bowel, bladder, ureter, diaphragm, or the space behind the cervix. A hysterectomy removes the uterus. It does not automatically remove disease outside it.

So the progestogen has a different possible job here: not protecting a lining you no longer have, but opposing estrogen’s effects on tissue that may remain.

Two rules save a lot of confusion:

Bleeding status is not disease status. Periods stopping does not show whether endometriosis remains.
Uterus status is not endometriosis status. They are separate facts about your body.

A third rule belongs beside them:

“Complete excision documented” is not a guarantee that no microscopic tissue exists. It is still stronger evidence than a memory of being told “we got it all.”

If endometriosis was the reason for your surgery, the ordinary shortcut is the wrong tool. It was built for a different woman.

Which HRT-and-endometriosis scenario are you actually in?

The right conversation depends on which operation you had, what remains, whether your ovaries are functioning, and what you are trying to treat. These are not small variations on one situation. They are different lanes with different first questions.

This is a map for a consultation, not a treatment plan. It does not choose a drug, dose, route, or schedule.

Your scenario	Confirm this first	What current evidence and guidance point toward discussing	Why the usual shortcut fails	Best starting point
1. Perimenopause or menopause, uterus intact, endometriosis history	Current pelvic symptoms, bleeding, prior endometrioma or deep disease	Combined systemic estrogen plus a progestogen if systemic HRT is used; European guidance generally prefers continuous combined therapy	The uterus already needs protection, and endometriosis adds a separate concern	Menopause clinician; in person first for active pelvic pain or abnormal bleeding
2. Hysterectomy, one or both ovaries retained	Whether the cervix remains, whether ovarian function continues, and what the operative report says	Do not assume an estrogen-only prescription is the whole conversation; raise the label exception	Removing the uterus does not remove endometriosis, and retained ovaries may still make estrogen	Records review before a regimen decision
3. Hysterectomy plus both ovaries removed, little or no residual disease documented	Age at surgery, pathology, wording of the operative report, current symptoms	HRT remains very much on the table, especially before the natural menopause age; combined therapy is the dominant guideline starting point	The uterine reason for a progestogen is gone, but the residual-disease question remains	Menopause clinician comfortable with surgical menopause
4. Hysterectomy plus both ovaries removed, known or possible residual deep disease	Location, size, bowel or bladder involvement, imaging, pathology	Specialist-led discussion; continuous combined therapy is generally preferred when systemic HRT is used	A generic intake form cannot resolve a decision driven by deep residual disease	In-person gynecologist or endometriosis specialist with menopause expertise
5. Both ovaries removed, uterus retained	Uterus and cervix status, age, bleeding history	Systemic estrogen needs a progestogen for the uterus; endometriosis adds another reason for specialist input	Two reasons now stack	Menopause clinician with gynecology involvement
6. Subtotal or supracervical hysterectomy	Whether the cervix and any endometrial tissue remain; exact surgical wording	Treat anatomy as unconfirmed until the report is read	“Partial” and “total” describe the uterus, not the ovaries or residual endometriosis	Records review before any regimen decision
7. GnRH medicine with add-back therapy	Drug, duration, add-back ingredients, bone plan	Coordinate with the prescribing gynecology team; do not layer a separate HRT plan on top without them	Add-back for active endometriosis is not the same as menopausal HRT	The team prescribing the GnRH medicine
8. Vaginal dryness, painful sex, or urinary symptoms only	Cause of pain, any bleeding, any new pelvic symptoms	Low-dose local vaginal therapy is a separate exposure question from systemic HRT	You may not need a systemic regimen decision at all	Menopause or gynecology clinician; see vaginal estrogen

One warning about scenario 3: “My surgeon said everything was gone” may be exactly right. It is still not the same evidence as an operative report that records complete excision, lists the sites treated, and states whether anything was left in place.

You are allowed to know which one you have.

What did the HRT-and-endometriosis studies actually find?

The published outcome evidence is small, old, heterogeneous, and partly overlapping. No trial proves that combined HRT prevents recurrence, no trial proves estrogen-only causes recurrence, and no dataset can produce your personal percentage. The largest updated cohort found no statistically significant difference among no HRT, estrogen-only, combined therapy, and tibolone.

That is the whole evidence problem in four sentences. Here is the ledger.

Study	Design and population	Regimens	Follow-up	What happened	What it can and cannot tell you
Fedele 1999	Randomized trial; 21 women with known residual deep endometriosis after ovary removal	Transdermal estradiol-based therapy vs tibolone	12 months	Moderate pelvic pain: 4 of 10 in the estradiol group vs 1 of 11 in the tibolone group; difference not statistically significant	Tiny study, short follow-up, and tibolone is not FDA-approved in the U.S. It cannot establish a safer regimen
Matorras 2002	Prospective randomized study; 172 women after bilateral ovary removal, 91.8% also hysterectomized	Transdermal estradiol plus cyclic oral micronized progesterone, n=115, vs no HRT, n=57	Mean 45 months	Recurrence: 4 of 115 vs 0 of 57; p=0.32, not statistically significant. Two women required repeat surgery	Shows that recurrence can occur on combined therapy. It does not prove combined HRT caused recurrence or that no HRT is safer
Rattanachaiyanont 2003	Retrospective; 107 women after hysterectomy and bilateral ovary removal	No HRT n=17; estrogen-only n=50; cyclic combined n=16; continuous combined n=24	Mean 41.2 months	One confirmed disease recurrence and three symptom recurrences were reported in the estrogen-only group; none in the other groups	Directionally important, but small and nonrandomized. This is a precursor cohort that overlaps with the later 2022 report below
Cheewadhanaraks 2013	Prospective cohort; 161 women after definitive surgery	Estrogen-only n=93 vs continuous estrogen plus progestin n=68; treatment depended on calendar era, not random assignment	36 months	Pain recurrence was 8.2% vs 2.9%; the difference was not statistically significant	Suggests a possible direction but cannot separate regimen effects from time, selection, or other differences
Tanmahasamut 2022	Retrospective updated cohort; 330 women after hysterectomy and bilateral ovary removal	No MHT n=43; estrogen-only n=230; estrogen plus progestogen n=39; tibolone n=18	Median about 6 years	Recurrence: 0, 7 (3.0%), 3 (7.7%), and 0; overall p=0.174. No malignant transformations were recorded	Largest comparative cohort, but nonrandomized and overlapping with the 2003 center cohort. It shows that recurrence was not confined to estrogen-only therapy

What this supports

The evidence supports a few things — and only a few:

Recurrence after surgical menopause is possible with or without HRT.
Recurrence has been reported on estrogen-only and combined regimens.
Small older datasets created a signal around unopposed estrogen, which is one reason guidelines prefer combined therapy.
The largest updated cohort did not find a statistically significant association between regimen and recurrence.
Known residual disease and incomplete surgery matter enough to belong at the center of the discussion.

What it does not prove

We are going to be blunt, because the internet is not.

It does not prove combined HRT prevents recurrence.
It does not prove estrogen-only HRT causes recurrence.
It does not prove tibolone is safer.
It does not tell you whether micronized progesterone, medroxyprogesterone acetate, norethindrone acetate, an IUD, or another progestogen suppresses residual disease better.
It does not tell you how long a hysterectomized woman should stay on a progestogen.
It cannot give you a personal percentage. Anyone who hands you one has made it up.

The 2009 Cochrane review found only two randomized trials and could not settle the question. Seventeen years later, the evidence is larger but not decisive.

That is not a reason to refuse treatment. It is a reason to stop pretending this is a one-line rule.

Why did your doctor and your friend’s doctor give opposite advice?

Current recommendations genuinely differ. ESHRE and EMAS say to avoid estrogen-only therapy in women with an endometriosis history, while the British Menopause Society prefers continuous combined HRT but allows a narrow later estrogen-only option for hysterectomized women with very little or no residual disease.

The disagreement is real. It is documented. It is not you misunderstanding.

What current guidance says side by side

Source	Date	Regimen recommendation	What the certainty language really means
ESHRE Endometriosis Guideline	2022	Combined MHT may be considered after natural or surgical menopause; clinicians should avoid estrogen-only regimens; after surgical menopause, combined estrogen-progestogen should continue at least to the natural menopause age	The combined-MHT recommendation is weak and based on low-certainty evidence; the estrogen-only warning is stronger but still rests heavily on case reports and limited observational data
EMAS clinical guide	2025	Continuous combined therapy is preferred in hysterectomized and non-hysterectomized women; estrogen-only therapy should be avoided	An evidence review plus expert consensus. It also says treatment must be personalized and recurrence management may include changing or stopping the regimen
British Menopause Society clinician tool	February 2026	Continuous combined HRT is preferred after hysterectomy. Estrogen-only may be considered after initial continuous-combined HRT in a hysterectomized woman with very little or no residual disease, especially beyond the natural menopause age. Continuous combined remains preferred for extensive peritoneal disease	This narrow exception prevents a blanket claim that every European source rules out estrogen-only therapy in every case. BMS also says the absolute recurrence and malignant-transformation risks cannot be quantified
Current FDA-approved estrogen labels	February 2026 and current product records	Some hysterectomized women with an endometriosis history may benefit from a progestogen; consider it when residual disease is known	Product labeling identifies the exception but does not choose a universal regimen or duration
Public U.S. society materials searched	Checked August 6, 2026	We did not locate a current ACOG or Menopause Society regimen recommendation written specifically for this population	“We did not locate” is not the same as claiming none exists. The FDA label remains the most specific current U.S. primary-source wording we found

That BMS row changes the clean story. European recommendations do not all say the exact same thing.

The dominant direction is still combined therapy. The difference is that BMS gives clinicians a narrow place to discuss estrogen-only later, after initial combined therapy, when the uterus is gone, residual disease is very limited or absent on the record, and the breast-risk trade-off becomes more important with age.

What clinicians actually prescribe

Amer and Bazmi surveyed 216 UK clinicians who manage surgical menopause after pelvic clearance for endometriosis. The questionnaire was reviewed by the British Menopause Society and the British Society for Gynaecological Endoscopy. This is practice-pattern data, not proof that any regimen is safer.

Regimen	Share of surveyed clinicians
Combined HRT	68.6%
Estrogen-only HRT	13.0%
Tibolone	11.1%
Varies case by case	7.8%

Among clinicians who used a progestogen, duration also varied:

Duration	Share of surveyed clinicians
Indefinitely	51%
3 to 6 months	22%
Varies	27%

There is no agreed answer to “for how long?” That is not a gap in your understanding. It is a gap in the evidence.

What is the honest trade-off of adding a progestogen?

Adding a progestogen is not a risk-free move. Combined therapy is the guideline-favored approach for endometriosis, but breast-risk data differ between estrogen-alone and estrogen-plus-progestogen regimens, and the best endometriosis-specific progestogen, dose, and duration have never been established.

This is where most pages stop being useful, so we are going to keep going.

The current Divigel label reports the Women’s Health Initiative estrogen-alone trial in hysterectomized women. That trial used oral conjugated equine estrogen 0.625 mg, not every form of estradiol. In that specific trial, invasive breast cancer occurred less often in the estrogen-alone group than in placebo: relative risk 0.79, an absolute difference of 7 fewer cases per 10,000 woman-years overall. That result cannot be pasted onto every dose, route, duration, or woman.

The estrogen-plus-progestin WHI trial used oral conjugated equine estrogen plus medroxyprogesterone acetate and found a higher invasive-breast-cancer signal. That does not prove every progestogen has the same breast profile, and it does not answer whether adding one prevents endometriosis recurrence.

So when the label and European guidance point toward combined therapy, you are not being offered a free safety upgrade. You are trading one uncertain concern against another better-documented set of regimen differences.

That is the damaging admission. Here is the pivot that keeps it from becoming a dead end:

The trade is not the same for every woman. A 39-year-old whose operative report says a rectovaginal nodule was left in place is not making the same decision as a 57-year-old whose report documents complete excision and who has a strong breast-risk reason to minimize progestogen exposure.

The guidelines do not erase that difference. The newest BMS tool builds it into the recommendation.

If a progestogen is genuinely off the table for you — because of a personal cancer history, a specialist’s recommendation, or repeated intolerance — do not guess and do not quietly abandon symptom treatment. Bring the operative report to the clinician managing that risk and review non-hormonal menopause options alongside the HRT choices that remain.

Which side of this trade-off actually applies to your history? Use Find My HRT Path to sort your care route before you choose a provider. It will tell you when an online clinic is a reasonable first stop and when this belongs in a room with a specialist.

What surgery detail changes the HRT decision most?

The operative report is the most useful missing document because it records what was removed, what was left, where the disease was, and whether the surgery was complete. It is not the only determinant, and “complete excision” cannot exclude microscopic disease, but it is far stronger than reconstructing surgery from memory.

In the Matorras trial, peritoneal involvement larger than 3 cm and incomplete surgery were associated with recurrence among women receiving HRT. Those were exploratory findings from a small number of events, not a validated personal-risk calculator. They still point toward the same practical question current guidance asks: what remains?

What to look for in the operative report

Wording you might see	What it tells the next clinician	What it does not prove
“Complete excision,” “all visible disease excised,” “no residual disease”	The surgeon documented removal of visible disease	That no microscopic disease exists
“Residual disease left in situ,” “unable to excise,” “not resected”	Known disease remains	How active it is now
“Rectovaginal nodule,” “bowel involvement,” “ureterolysis,” “deep infiltrating endometriosis”	Deep disease or high-complexity anatomy was involved	That every listed site still contains disease
“Adhesiolysis”	Adhesions were divided	That endometriosis itself was excised
“Bilateral salpingo-oophorectomy” or “BSO”	Both ovaries and fallopian tubes were removed	That all extra-ovarian endometriosis was removed
“Ovaries conserved,” “left ovary preserved”	Ovarian function may continue	How much estrogen the ovary is producing now
“Supracervical” or “subtotal hysterectomy”	The cervix remains	Whether endometrial tissue remains or what happened to the ovaries
“Specimens submitted to pathology”	A second record may confirm the tissue diagnosis	That every lesion was sampled
ASRM stage I–IV	A surgical severity classification was recorded	The exact current recurrence risk or the best HRT regimen

The trap almost everyone falls into: “partial” versus “total” hysterectomy describes the uterus. It tells you nothing about whether the ovaries came out and nothing about whether endometriosis remained.

How to request the records

Ask the surgeon’s office or hospital medical-records department for:

The complete operative report
The pathology report
Relevant preoperative and postoperative imaging reports
The discharge summary if it contains the only clear anatomy list

Copy this:

“I’m requesting an electronic copy of my complete operative report, pathology report, discharge summary, and relevant imaging reports from my surgery on [date] with [surgeon]. Please tell me if you need a records-request form and send the records directly to me in an electronic format if available.”

Under the HIPAA right of access, a covered entity generally has up to 30 calendar days to act on a request. It may take one additional 30-day extension if it gives a written reason and a completion date. Any fee must be reasonable and cost-based for permitted copying, supplies, and postage; a retrieval or search fee is not part of the permitted patient-access charge. State law may give you stronger rights.

Do not promise yourself the report will arrive in a few business days. It might. The federal outside limit is longer.

You do not need to diagnose yourself from the document. You need to have it so the person choosing your regimen is looking at facts instead of a shrug.

Why does early or surgical menopause change the calculation?

Women with endometriosis are much more likely to reach menopause through surgery, often earlier than women without endometriosis. A 2025 pooled analysis of 279,948 women found a 7.54-fold higher risk of surgical menopause and an average surgical-menopause age 19 months earlier in women with endometriosis.

This is the half of the ledger that disappears when the conversation is only about recurrence.

The InterLACE analysis pooled individual-level data from five cohort studies in the United Kingdom, Australia, Sweden, and Japan. About 3.7% of participants had endometriosis. Compared with women without endometriosis, they had:

A 7.54-fold higher risk of surgical menopause
Surgical menopause an average of 19 months earlier
Natural menopause an average of about 4 months earlier
Higher odds of premature surgical menopause and spontaneous premature ovarian insufficiency

It was observational. It cannot prove that endometriosis itself caused every difference, and it cannot choose an HRT regimen. It does establish that early and surgical menopause are not rare side plots in this diagnosis.

That matters because abrupt estrogen loss before the natural menopause age has consequences of its own. ESHRE highlights bone-density, cardiovascular, and cognitive concerns after early bilateral ovary removal. EMAS and BMS recommend estrogen-based treatment through the average natural-menopause age for women with premature or early menopause unless a specific contraindication changes the plan.

So the decision is not “risk versus safety.” It is risk versus a different risk.

“Just avoid hormones to be safe” is not the neutral choice it sounds like — especially when both ovaries came out before 45. A careful decision has to hold the recurrence concern and the cost of untreated early estrogen loss at the same time.

Our HRT benefits and risks guide covers the other side of that ledger in full.

Can endometriosis come back after menopause?

Yes. Endometriosis usually becomes less active as ovarian estrogen falls, but persistent, recurrent, and newly diagnosed postmenopausal disease are all documented. Reviews often repeat an estimated postmenopausal prevalence around 2% to 5%, but the underlying population data are sparse, so that range is not a personal probability.

Two different things can happen:

Persistent or recurrent disease. Lesions that existed before menopause remain or become symptomatic again.
Disease first diagnosed after menopause. A woman presents with pain, bleeding, urinary or bowel symptoms, or a pelvic mass and receives the diagnosis for the first time.

Postmenopausal estrogen does not fall to zero. Peripheral tissues continue to produce estrogen, and exogenous exposure can come from hormone therapy. None of that means every postmenopausal lesion is active or that HRT automatically causes recurrence.

What should change your behavior is not the existence of a scary percentage. It is the symptom pattern.

EMAS lists abdominal or pelvic pain, vaginal bleeding, blood in the urine, and pelvic masses among possible recurrence presentations. It also says manifestations can be nonspecific. That is why new symptoms should not be waved away as “just the HRT” or assumed to be endometriosis without evaluation.

Can endometriosis become cancerous after menopause or on HRT?

Malignant transformation is documented but rare, and current evidence cannot quantify the absolute risk caused by HRT. Case reports disproportionately involve long-term estrogen-only exposure, but case reports cannot calculate incidence, prove causation, or tell you your personal risk.

Let’s put the usable numbers first, because fear expands to fill whatever space you leave empty.

The strongest modern absolute-risk anchor is not HRT-specific

A 2024 JAMA cohort included 450,906 women, including 78,893 with endometriosis. Endometriosis was associated with an adjusted hazard ratio of 4.20 for ovarian cancer and an adjusted risk difference of 9.90 additional ovarian cancers per 10,000 women in the study analysis. Deep infiltrating endometriosis or ovarian endometriomas carried a higher association than other endometriosis subtypes.

That study did not answer whether menopausal HRT caused the excess. It was not a lifetime-risk calculator, and it did not compare estrogen-only with combined MHT in surgical-menopause patients.

The HRT-specific malignant-transformation literature is case-only

A 2021 systematic review assembled 90 unique postmenopausal patients with malignant transformation of endometriosis from published case reports and series. HRT information was available for 74; 49 had used HRT, and roughly three-quarters of those users had received estrogen-only therapy. Median HRT duration was long.

That pattern is one reason ESHRE and EMAS reject estrogen-only therapy and why FDA labels mention malignant transformation of residual implants. It still cannot tell you how often the event happens among all women taking HRT.

The British Menopause Society says the absolute risks of reactivation and malignant transformation cannot be quantified from current evidence.

That sentence belongs here in bold:

No responsible page can give you a reliable personal malignant-transformation percentage from HRT.

Two action points survive the uncertainty:

Case reports are a signal, not a denominator. They tell you what has happened, not how likely it is to happen to you.
New symptoms get evaluated. Any bleeding after menopause, a new pelvic mass, blood in urine or stool, unexplained weight loss, or persistent new pain needs prompt assessment.

No product. No provider. No CTA. Go to a clinician.

What HRT options exist in the United States after endometriosis?

The U.S. options include estrogen with a continuous progestogen, estrogen with a cyclic progestogen, estrogen alone in selected cases, and systemic estrogen paired with a 52 mg levonorgestrel IUD when a uterus is present. Tibolone appears in European guidance but has no FDA-approved U.S. product.

Option	U.S. regulatory status	What the endometriosis evidence says	Main trade-off
Systemic estrogen plus a continuous progestogen	FDA-approved estrogen and progestogen products are available as separate prescriptions; some fixed combinations are approved for women with a uterus	Preferred by EMAS and BMS and consistent with ESHRE’s combined-therapy direction. No trial proves it prevents recurrence	Progestogen tolerability and regimen-specific breast-risk questions; no established “best” molecule for residual disease
Systemic estrogen plus a cyclic progestogen	FDA-approved separate products are available	Used in the Matorras trial; recurrences occurred despite combined cyclic therapy. Less favored than continuous exposure in current European guidance	Scheduled bleeding may occur with a uterus; endometriosis-specific superiority has not been tested
Estrogen alone	FDA-approved products available; ordinary default after hysterectomy	ESHRE and EMAS say avoid it. FDA labels flag the endometriosis exception. BMS allows a narrow later path after initial continuous-combined therapy when little or no disease remains	May reduce progestogen exposure, but residual-disease and malignant-transformation concerns remain
52 mg levonorgestrel-releasing IUD plus systemic estrogen	The IUD is FDA-approved for contraception and heavy menstrual bleeding; using it as the progestogen component of menopausal HRT is off-label in the U.S.	Included as an option in BMS guidance for women with a uterus; no trial proves it suppresses residual endometriosis better than systemic progestogens	Requires a uterus and insertion; off-label for this purpose in the U.S.
Tibolone	No FDA-approved product identified in Drugs@FDA as of August 6, 2026	Appears in European guidance and small studies; one tiny trial did not establish superiority	Not a U.S. option
Aromatase inhibitor for recurrent disease	Drugs exist, but use for postmenopausal endometriosis is off-label	ESHRE and EMAS reserve this as a specialist option when recurrence is symptomatic and surgery is not feasible or appropriate	Bone loss, vasomotor symptoms, dryness, and case-level evidence in this population; not routine menopausal HRT

Micronized progesterone versus synthetic progestins

They are not interchangeable in the evidence, and no trial has established that one is best for suppressing residual endometriosis.

Matorras used oral micronized progesterone cyclically.
Some cohort regimens used medroxyprogesterone acetate.
The 2022 cohort grouped therapies rather than proving molecule-level differences.
BMS and EMAS recommend a regimen class, not one universally superior U.S. product.

If a clinician says one molecule is clearly proven best for residual endometriosis, ask for the study. That is a legitimate question. The settled answer does not exist.

Does the estrogen route matter — patch, gel, pill, or vaginal?

No published study has compared endometriosis recurrence by estrogen route. Current endometriosis warnings appear on the representative oral, gel, and patch labels we checked, but warning language does not prove that all routes create the same systemic exposure or recurrence risk.

Route matters for other reasons. Oral and transdermal estrogen differ in first-pass liver exposure, and current menopause guidance often prefers transdermal estrogen when clotting or metabolic risk makes route relevant. That evidence is about thromboembolic and other systemic outcomes — not endometriosis recurrence.

So do not let anyone tell you that a patch “solves” the endometriosis question. It may be the right route for other reasons. The residual-disease question remains.

Vaginal estrogen is a different decision

If the problem is vaginal dryness, painful sex, or urinary irritation without vasomotor symptoms, you may not need a systemic HRT decision at all.

Low-dose local vaginal estrogen is intended to treat genitourinary tissue, not hot flashes. The February 2026 BMS tool says vaginal estrogen can be used with or without systemic HRT in women with endometriosis, and EMAS includes locally applied estrogen among treatments for genitourinary syndrome of menopause.

That does not erase the need to evaluate unexplained bleeding or new pelvic pain. It means local treatment should not be casually treated as identical to full-dose systemic estrogen.

See our complete guide to vaginal estrogen.

When should you start HRT after endometriosis surgery?

There is no agreed ideal interval. One retrospective study found no greater recurrence of pain when estrogen started within six weeks of hysterectomy and ovary removal than when it started later, while the British Menopause Society says current evidence is too uncertain to set a universal post-surgical waiting period.

Hickman and colleagues reviewed 95 women after hysterectomy with bilateral ovary removal for endometriosis:

60 started estrogen within six weeks; 4 (7%) had recurrent pain.
35 started after six weeks; 7 (20%) had recurrent pain.
The crude difference was not statistically significant; after adjustment, delayed treatment was associated with more recurrence, but the confidence interval was wide.

This was not a randomized trial. The later-start group may have differed in ways the analysis could not fully remove. It does show that the common instruction to wait three to six months is not backed by evidence that waiting is safer.

Waiting is not free either, especially after ovary removal before 45. The abrupt hormone drop creates immediate symptoms and longer-term bone and cardiovascular concerns.

So the accurate answer is not “start immediately” or “always wait.” It is:

There is no proven universal delay. Ask which evidence your prescriber is following and how the amount of residual disease changes the timing for you.

What changes if you still have your uterus?

A woman with a uterus needs a progestogen alongside systemic estrogen to reduce endometrial-cancer risk, regardless of endometriosis. The open questions are which progestogen, whether it is continuous or cyclic, how it is delivered, and how active endometriosis changes follow-up.

You still get the endometriosis consideration. It simply stacks on top of a uterine requirement that already exists.

ESHRE, EMAS, and BMS all point toward combined therapy. EMAS and BMS prefer continuous combined exposure in this population. The evidence behind the endometriosis-specific preference is limited; the uterine-protection requirement is not.

If systemic progestogens make you feel awful, that is a real treatment problem with options to discuss — different molecules, doses, schedules, or, when appropriate, a 52 mg levonorgestrel IUD. Quietly stopping the progestogen while continuing systemic estrogen is not the workaround.

Not sure which anatomy lane is yours? Find My HRT Path sorts the care route by what was removed, what remains, symptoms, state, and risk history — and flags when online care should not be your first stop.

What if you are taking a GnRH medicine with add-back therapy?

GnRH agonists and antagonists lower estrogen to treat active endometriosis; add-back therapy returns a controlled amount of hormone to reduce bone loss and hypoestrogenic symptoms. That is an endometriosis-treatment regimen, not a separate menopausal-HRT plan.

Medicines in this category include leuprolide, elagolix, and relugolix-containing regimens. Their labels differ in indication, composition, contraindications, and duration limits.

The practical rule is simple:

Do not layer a separate online HRT prescription on top of a GnRH regimen without the prescribing team seeing the whole plan.

This is not because every combination is forbidden. It is because two hormone plans can work against each other, duplicate ingredients, change bone protection, or create an exposure the individual prescribers did not intend.

If you are on this pathway and having menopause-like symptoms, start with the gynecology team managing the endometriosis treatment.

Why does an FDA-approved endometriosis drug contain estradiol?

Myfembree, an FDA-approved treatment for moderate to severe endometriosis pain in premenopausal women, contains 1 mg of estradiol in every daily tablet. It pairs that estrogen with relugolix and norethindrone acetate to reduce the hypoestrogenic effects of ovarian suppression while protecting the uterine lining.

Each tablet contains:

Relugolix 40 mg
Estradiol 1 mg
Norethindrone acetate 0.5 mg

Use is limited to 24 months because bone loss may continue and may not be fully reversible. Myfembree is not menopausal HRT, is not indicated for postmenopausal women, and does not prove that systemic estrogen is harmless after endometriosis surgery.

So why include it?

Because many women have been taught that “estrogen plus endometriosis” is always a contradiction. The FDA-approved architecture is more precise than that. In an active-disease treatment, estrogen can be deliberately paired with ovarian suppression and a progestin to reduce treatment harms without abandoning the therapeutic design.

Lupron Depot add-back labeling uses a related principle: norethindrone acetate is added to reduce bone-density loss and vasomotor symptoms during leuprolide treatment, with a strict duration limit.

The inference has boundaries:

It does not make Myfembree a menopausal-HRT option.
It does not prove one menopausal regimen is safe for you.
It does show that estrogen exposure can be part of a deliberate endometriosis treatment architecture rather than an automatic mistake.

You have been asking for permission to treat your symptoms. The permission is not ours to give; it belongs to the prescriber who knows your history. But the idea that estrogen is simply forbidden does not survive contact with the FDA’s own approvals.

What should you do if pelvic symptoms return after starting HRT?

Contact the prescriber promptly for new or returning pelvic symptoms. Do not use this page to make an unsupervised stop, restart, dose, or regimen change. Recurrence is one possibility; urinary, bowel, gynecologic, musculoskeletal, and malignant conditions can produce overlapping symptoms.

Call the clinician who prescribed HRT for:

New pelvic pain or pain that resembles your old endometriosis pain
Pain with bowel movements or urination
Pain with sex that is new or worsening
Persistent bloating, pressure, or fullness
A meaningful change in a known symptom pattern

Seek prompt in-person evaluation for:

Any vaginal bleeding after menopause
Blood in your urine or stool
A lump or mass you can feel
Severe or rapidly worsening pain
Unexplained weight loss

Current EMAS guidance does not impose one automatic response to symptoms. Depending on the evaluation, management can include altering the regimen, discontinuing MHT, using non-hormonal options, imaging, surgery, or other specialist treatment.

That is why “stop immediately no matter what” and “keep taking it no matter what” are both too rigid.

Do not make the decision alone at 2 a.m. with a search engine open. Call the person who wrote the prescription and get the symptom evaluated.

Can an online HRT clinic handle a history of endometriosis?

Online care can fit a stable, well-documented case, but the clinician must be willing and able to review the surgical history that changes the regimen. Known residual deep disease, a subtotal hysterectomy, missing records, new pelvic symptoms, or any red flag belongs in person first.

Online care may be a reasonable starting point when

Your surgery and anatomy are clearly documented
The operative report records little or no residual disease
Your symptoms are typical menopause symptoms rather than new pelvic symptoms
You have no unexplained bleeding or pelvic mass
The clinic offers a real clinician visit, record review, and follow-up
The exact medication category is disclosed before you agree to it

Start in person when

Deep or residual disease is known or strongly suspected
Bowel, bladder, ureter, diaphragm, or rectovaginal disease was involved
You cannot obtain or explain the surgical records
You had a subtotal or supracervical hysterectomy and anatomy is unclear
Old pelvic pain is returning or new symptoms have appeared
A personal cancer history requires oncology coordination

What to verify before you pay

Will a licensed clinician speak with you live? A questionnaire cannot interrogate an operative report.
Will that clinician review uploaded surgical records? Ask before checkout. Neither provider page below publicly guarantees this exact service for every appointment.
Which exact medication will be prescribed if treatment is appropriate? Keep FDA-approved products and compounded preparations in separate categories. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
What is the visit price, what does insurance cover, and what is separate? Include labs, medication, imaging, and follow-up.
What is the cancellation policy? A complex case may need a different clinician than the first one you book.
What happens if pain or bleeding appears after treatment starts? Follow-up is part of the decision, not an optional extra.

The two routes we would check first

These are editorial starting points, not guarantees of treatment. The review links below may contain labeled affiliate links.

Midi Health: first look for a live menopause-care model

Midi publishes live-clinician care and nationwide insurance-coverage language on its current pricing page. As of August 6, 2026:

Provider-stated Midi fact checked August 6, 2026	Current detail	What it means here
Cash price	$250 initial visit; $150 continued-care visit	These are published visit prices, not an all-in medication, lab, or imaging quote
Insurance	In-network with most PPO plans; plan-specific copays, deductibles, and coinsurance still apply	Confirm the exact medical group and plan before booking
Medicaid / Medi-Cal	Midi says it cannot treat these patients, even as self-pay	Hard stop
Medicare	Not covered; beneficiaries may self-pay but cannot submit Midi-related claims	Not a Medicare-covered route
Medication category	Midi offers FDA-approved menopause options and also has a separate custom-compounded program	Ask for the exact product and keep the categories separate
Operative-report review	No public guarantee found for every visit	Ask before paying and before assuming the clinic can resolve this page’s decision

Midi does not solve the hard part just because it is a menopause clinic. If it will not review your report, it is the wrong visit for this decision. If it will, a live menopause-care model is structurally better suited than an asynchronous prescription questionnaire.

Does that sound like the conversation you need? Read our verified Midi Health review and check your plan before booking →

Sesame: better when you need to choose an individual clinician or local service

Sesame is a cash-pay marketplace, not one uniform HRT clinic. It may list telehealth or in-person gynecology, labs, or imaging depending on location and provider availability.

Provider-stated Sesame fact checked August 6, 2026	Current detail	What it means here
Price	Provider- and service-specific; the price is displayed before booking	Do not use a general “from” price as a gynecology quote
Insurance	Sesame does not accept Medicare, Medicaid, or other third-party insurance for provider visits	Cash-pay route
Virtual cancellation	Full refund when canceled at least 3 hours before the visit	Miss the window and the charge may stand
In-person cancellation	Full refund when canceled at least 24 hours before the visit	Useful when choosing a local clinician
Prescription outcome	No refund because a prescription was not issued or because you disagree with the clinical outcome	Paying for evaluation does not guarantee HRT
Operative-report review	Provider-specific; no marketplace-wide promise	Ask the individual clinician before booking

Sesame is not automatically “better” for endometriosis. Its advantage is that you may be able to choose a specific gynecologist or in-person service and see the price before booking. Its weakness is inconsistency: the experience depends on the individual listing.

If what you need is a clinician who can examine you or read records in context, review Sesame’s current model, pricing, and booking limits before you choose a listing →

The right answer may still be neither. Find My HRT Path is the safer first click when you are not sure whether this is an online-care case at all.

How did The HRT Index research this page?

This page is editorial research by The HRT Index. It has not been reviewed by a clinician, and we say that at the top rather than implying otherwise. Every drug-label statement was checked against current FDA or DailyMed material; every outcome study is named with its design, size, and limitations.

Our framework is The HRT Index Verification Standard. We read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, the full roster quarterly.

We evaluate providers on five things, in this order:

Clinical legitimacy
Care quality
Medication fit
Price transparency
Access

We do not publish numeric provider scores. A single number would hide the exact trade-offs this page exists to show.

Provider-stated versus independently verified

Claim type	How it is labeled here
Current visit price, insurance language, cancellation term	Provider-stated, linked to the provider’s current page and dated August 6, 2026
FDA approval, indication, warning, contraindication	Checked against FDA or DailyMed primary material
Study result	Linked to the peer-reviewed publication or PubMed record, with design and limitations visible
“Who this may fit”	The HRT Index editorial conclusion based on the verified facts above
Anything not publicly promised	Marked as something to confirm during booking rather than guessed

Why there are no testimonials on this page

A testimonial about doing well on a specific regimen would function as a safety or effectiveness claim in a population where no menopausal product has an endometriosis indication and the trials are inadequate. One woman’s outcome is not your denominator.

Women describe the confusion in almost identical words: they were told estrogen is forbidden, then handed estrogen-only after surgery; one clinician says progesterone is essential, another says it adds unnecessary breast risk; the information feels “all over the place.”

That experience is real. It is still not medical evidence.

Corrections: If a source changes or something here is wrong, send us a correction →. We would rather publish the change than defend the mistake.

What else do women ask about HRT and endometriosis?

Do I need progesterone if I had a hysterectomy for endometriosis?

Possibly. Current FDA-approved estrogen labels we checked say some hysterectomized women with an endometriosis history may benefit from a progestogen and tell prescribers to consider one when residual disease is known. ESHRE and EMAS prefer combined therapy. BMS allows a narrow later estrogen-only option after initial continuous-combined HRT when little or no disease remains.

Can HRT make endometriosis come back?

Recurrence has been reported on estrogen-only and combined regimens. The largest updated cohort found no statistically significant difference among no HRT, estrogen-only, combined therapy, and tibolone. No reliable universal percentage exists.

Did every recurrence in the studies happen on estrogen-only HRT?

No. That was true in the small 2003 Thai report, but the larger 2022 update from the same center included overlapping patients and recorded seven recurrences on estrogen-only therapy and three on estrogen-plus-progestogen therapy. The final page uses the updated evidence and discloses the overlap.

How long should I stay on the progestogen after hysterectomy?

There is no agreed duration. In a UK survey of 216 clinicians, 51% continued it indefinitely, 22% used it for three to six months, and 27% varied. Practice variation is not proof, but it shows the evidence gap plainly.

Is estrogen-only HRT ever considered after endometriosis?

Yes, but current guidance narrows the lane. ESHRE and EMAS say to avoid it. The February 2026 BMS tool says it may be considered after initial continuous-combined HRT in a hysterectomized woman with very little or no residual disease, especially after the natural menopause age, with individual breast and recurrence risks weighed together.

Can endometriosis become cancerous after menopause?

Malignant transformation is documented and rare, but current evidence cannot quantify the personal risk caused by HRT. Case reports disproportionately involve long-term estrogen-only exposure. New bleeding, a pelvic mass, blood in urine or stool, unexplained weight loss, or persistent new pain needs prompt evaluation.

Is tibolone available in the United States?

No FDA-approved tibolone product was identified in Drugs@FDA as of August 6, 2026. It appears in European guidance and studies, which is why a British page may discuss an option a U.S. prescriber cannot offer.

Can I use a hormone IUD instead of an oral progestogen?

A 52 mg levonorgestrel IUD can be paired with systemic estrogen when a uterus is present, and BMS includes that route. In the U.S., using the IUD for the progestogen component of menopausal HRT is off-label; FDA indications are contraception and heavy menstrual bleeding.

Should I wait three to six months after surgery before starting HRT?

No trial proves that delay is safer. One retrospective study found no higher recurrence of pain in women who started estrogen within six weeks than in women who started later. BMS says there is no clear consensus on the ideal interval, so timing should reflect age, symptoms, residual disease, and the prescriber’s reasoning.

I still have my uterus. Can I use HRT with endometriosis?

Often, yes. If systemic estrogen is used, a progestogen is needed to protect the uterine lining. Current European guidance generally prefers continuous combined therapy in women with an endometriosis history.

Does a patch avoid the endometriosis concern?

No recurrence study has compared patch, gel, pill, injection, or another estrogen route. A current estradiol patch label contains the same type of endometriosis warning and hysterectomy exception. A patch may be chosen for other risk reasons, but it does not erase the residual-disease question.

Is vaginal estrogen the same decision as systemic HRT?

No. Low-dose local vaginal estrogen treats genitourinary symptoms and is addressed separately in BMS and EMAS guidance. Any unexplained bleeding or new pelvic pain still needs evaluation before it is treated as ordinary dryness.

What should I do if pelvic pain returns after I start HRT?

Contact the prescriber promptly and arrange evaluation. Do not use an article to make an unsupervised stop, restart, or dose change. Bleeding after menopause, blood in urine or stool, a mass, severe pain, or unexplained weight loss needs prompt in-person assessment.

My surgeon said everything was removed. Is that enough?

It may be correct. The operative report is still stronger evidence because it records which sites were treated, whether visible disease remained, whether the ovaries and cervix were removed, and what went to pathology. Request it.

Does endometriosis affect when menopause happens?

Yes at a population level. The 2025 InterLACE analysis found a 7.54-fold higher risk of surgical menopause among women with endometriosis and an average surgical-menopause age 19 months earlier. The study was observational and cannot choose your HRT regimen.

Can an online provider make this decision from a questionnaire?

A questionnaire alone cannot resolve a decision that turns on an operative report, residual deep disease, or new pelvic symptoms. Online care may fit a stable, documented case when a licensed clinician will review the records and follow up. Otherwise, start in person.

Where do you go from here?

If you take one thing from this page, take this: the answer is hiding in two documents you can obtain.

One is the current label for the exact estrogen product you were prescribed. The other is your operative report.

The women who get a real decision with this history are not the ones who memorized the most rules. They are the ones who walked in with the anatomy, the surgical facts, the current symptoms, and the questions the shortcut skipped.

Still not sure which HRT program is right for you? Use the free Find My HRT Path tool → It takes about 90 seconds, sorts the care route by your symptoms, history, preferences, budget, and state, keeps FDA-approved and compounded options separate, and tells you plainly when online care is not the right starting point.

Which sources support this page?

FDA and U.S. regulatory sources

Guidelines and clinical guidance

Outcome studies and systematic reviews

Menopause timing and cancer evidence

Provider facts verified August 6, 2026

Educational content only. Not medical advice, diagnosis, or a treatment plan. Do not start, stop, or change prescription hormone therapy without the clinician responsible for your care.

Take the operative report to the clinician who owns the unanswered question.

The source identifies the operative report, current anatomy, residual-disease history, symptom pattern, and competing risks as the facts that change this decision. If you need to compare care settings after those questions are documented, read our verified Midi Health review and verified Sesame HRT review. When you are not sure whether online care is appropriate, use Find My HRT Path first.

Keep reading: